Ocular surface lesions due to keratoconjunctivitis sicca: in primary Sj�gren's syndrome

1992 ◽  
Vol 79 (3) ◽  
pp. 277-284 ◽  
Author(s):  
S. Roncin ◽  
Y. L. Pennec ◽  
P. Katsikis ◽  
J. Colin ◽  
P. Youinou
Ophthalmology ◽  
2013 ◽  
Vol 120 (5) ◽  
pp. 883-891 ◽  
Author(s):  
Mohamed Abou Shousha ◽  
Carol L. Karp ◽  
Ana Paula Canto ◽  
Kelly Hodson ◽  
Patrick Oellers ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (12) ◽  
pp. e29017 ◽  
Author(s):  
Cintia S. De Paiva ◽  
Eugene A. Volpe ◽  
Niral B. Gandhi ◽  
Xiaobo Zhang ◽  
Xiaofen Zheng ◽  
...  

2021 ◽  
Vol 8 (1) ◽  
pp. 1-9
Author(s):  
Alfonso L Sabater ◽  

Autologous blood eye drops have become an interesting, well-known, and widely used therapeutic option for many ocular surface diseases since their introduction into the ophthalmologic field forty-six years ago. The foundation for their use in the treatment of pathologies such as severe keratoconjunctivitis sicca, persistent epithelial defects, ocular chemical burns, recurrent epithelial erosions, Stevens-Johnson syndrome, ocular graft versus host disease, and, lately, in many other ocular surface conditions, relies on the fact that they contain proteins, vitamins, cytokines, and growth factors that participate in the signaling pathways of corneal epithelial healing in similar amounts to those found in normal, healthy tear films


2014 ◽  
Vol 7 (3) ◽  
pp. 161
Author(s):  
MayankA Nanavaty ◽  
AnishN Shah ◽  
Rima Al-Sukkar ◽  
DamianB Lake

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Francesco Semeraro ◽  
Eliana Forbice ◽  
Osvaldo Braga ◽  
Alessandro Bova ◽  
Attilio Di Salvatore ◽  
...  

Purpose. This study evaluated the efficacy of 50% autologous serum eye drops in ocular surface diseases not improved by conventional therapy.Methods. We analyzed two groups: (1) acute eye pathologies (e.g., chemical burns) and (2) chronic eye pathologies (e.g., recurrent corneal erosion, neurotropic keratitis, and keratoconjunctivitis sicca). The patients were treated for surface instability after conventional therapy. The patients received therapy 5 times a day until stabilization of the framework; they then reduced therapy to 3 times a day for at least 3 months. We analyzed the best corrected visual acuity, epithelial defects, inflammation, corneal opacity, and corneal neovascularization. We also analyzed symptoms such as tearing, burning, sense of foreign body or sand, photophobia, blurred vision, and difficulty opening the eyelids.Results. We enrolled 15 eyes in group 1 and 11 eyes in group 2. The average therapy period was 16 ± 5.86 weeks in group 1 and 30.54 ± 20.33 weeks in group 2. The epithelial defects all resolved. Signs and symptoms improved in both groups. In group 2, the defect recurred after the suspension of therapy in 2 (18%) patients; in group 1, no defects recurred.Conclusions. Autologous serum eye drops effectively stabilize and improve signs and symptoms in eyes previously treated with conventional therapy.


2018 ◽  
Vol 53 (2) ◽  
pp. 150-154 ◽  
Author(s):  
Michael Yim ◽  
Anat Galor ◽  
Afshan Nanji ◽  
Madhura Joag ◽  
Sotiria Palioura ◽  
...  

2019 ◽  
Vol 1 (5) ◽  
pp. 292-302 ◽  
Author(s):  
Astrid Rasmussen ◽  
Donald U. Stone ◽  
C. Erick Kaufman ◽  
Kimberly S. Hefner ◽  
Nicole R. Fram ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document